Clinical trial · Interventional
Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma
Intratumoral Pressure, Intratumoral Partial Oxygen Pressure, and Inflammatory Cytokines in Antisecretory Factor Treatment of Glioblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this clinical trial is to investigate the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, in participants undergoing diagnostic biopsies for suspected glioblastoma. The primary questions the trial seeks to answer are: * Will Salovum® reduce intratumoral pressure? * Will Salovum® influence the release of inflammatory cytokines from tumor tissue? Additionally, the study will investigate the impact of Salovum® on intratumoral partial oxygen pressure and tumor volume. Researchers will: * Place probes for measuring intratumoral pressure, microdialysis, and partial oxygen pressure during a standard biopsy procedure. * Compare measurements from participants before and during ingestion of Salovum®. Participants will: * Have probes implanted during a surgical biopsy. * Ingest Salovum® 24 to 72 hours after the procedure.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Salovum | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Salovum
- description
- Ingestion of Salovum during 48 hours starting 24 hours after diagnostic biopsy
- interventionNames
- Dietary Supplement: Salovum
Primary outcomes (1)
- measure
- Intratumoral pressure after ingestion of Salovum®
- timeFrame
- 0 to 72 hours after diagnostic biopsy
- description
- To measure intratumoral pressure by insertion of catheters to measure pressure (Sophysa, France) before and during ingestion of Salovum® in participants diagnosed with glioblastoma (GBM) who undergo a diagnostic biopsy.
Secondary outcomes (1)
- measure
- Inflammatory cytokine release after ingestion of Salovum®
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Suspected glioblastoma 2. Age 18-75 years 3. Planned diagnostic biopsy 4. Informed consent of subject Exclusion Criteria: 1\. Known egg yolk allergy
References
Publications (0)
Data not yet available